Business Wire

KAYTUS

21.5.2024 12:18:30 CEST | Business Wire | Press release

Share
KAYTUS Introduces KR1280V2 - a 1U Server with 32 E1.S SSDs, Boosting I/O Performance for LLM Training

KAYTUS, a leading IT infrastructure provider, introduced at ISC High Performance 2024 its high-density computing server KR1280V2. It supports 32 E1.S SSDs, achieving an impressive flash memory density of 512TB in a 1U form factor. Compared to the last generation, KR1280V2 adopts low latency storage and network design, doubling the high concurrency I/O performance for LLM training scenarios, and improving model training efficiency.

This 1U2S flagship server is powered by the latest Intel, AMD, or ARM processors. The KR1280V2 features an optimized cooling strategy to support CPUs with the highest TDP across platforms, without configuration restrictions. It also introduces a novel front I/O configuration, enhancing scalability with 8 PCIe 5.0 expansion cards and improving maintenance efficiency in data centers. The server’s drive tray type has been optimized to offer an innovative storage configuration of 12 front SFF drives, increasing storage density by 20%.

Supports 32 E1.S SSDs without performance degradation, delivering tens of millions IOPS

Powered by 5th Gen Intel® Xeon® processors and boasting remarkable computing density, the KR1280V2 supports up to 32 all-flash E1.S SSDs directly connected to CPUs within a 1U form factor. This configuration harnesses the full I/O rate of PCIe 5.0, maximizing throughput between CPUs and storage, achieving up to 160GB/s storage throughput. With load balancing across two OCP 3.0 cards, it doubles network bandwidth, catering to diverse data storage and processing needs while enhancing overall computing performance by 60%.

With ultimate flash memory density, the KR1280V2 effectively doubles LLMs' high concurrency performance

The KR1280V2 achieves tens of millions of IOPS performance in distributed storage scenarios, marking a remarkable 77% improvement. Deploying KR1280V2 servers for large-scale LLMs training ensures a twofold increase in high-concurrency I/O performance compared to the previous generation. As the number of GPUs and workload increases, the KR1280V2's latency curve becomes smoother and more predictable, demonstrating a notable 13% improvement in data latency also compared to the prior generation. These significant advancements enhance data preparation efficiency, model training, and data management while reducing wasted storage space. Consequently, it delivers robust storage capacity and performance for innovative LLM applications and better supports Java-based business scenarios requiring massive data, low latency, and high concurrency, such as in finance, cloud services, enterprises, and other data center applications.

Optimized cooling technologies and exceptional business reliability and sustainability

In terms of heat dissipation, the KR1280V2 supports multiple cooling methods, including EVAC heatsink air cooling, cold-plated liquid cooling, and single-phase immersion liquid cooling. It achieves an 8% to 12% power reduction through fan partition regulation, one-click BIOS optimization, and other techniques across 17 energy-efficient scenarios. Additionally, the KR1280V2 employs numerous advanced technologies to enhance stability and security. It introduces the exceptional MUPR2.0 early detection memory fault function, which utilizes a more comprehensive memory scrubbing technique to self-check and fix memory faults, achieving a broader range of error correction and a higher level of system protection. Consequently, the system's downtime rate is 69% lower than the industry average.

To learn more about the KAYTUS KR1280V2 high-density server, please visit the website.

About KAYTUS

KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521588996/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye